

Please type a plus sign (+) inside this box → ☐

11-07-00

A

PTO/SB/05 (4/98)

Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53 (b))

Attorney Docket No. LEX-0083-USA

First Inventor or Application
Identifier

Brian Mathur et al.

Title

Novel Human Kinase Protein and Polynucleotides, the Same

Express Mail label No.

EL672756246US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1 ☐ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)

2 ☒ Specification [Total 28]
Pages
(preferred arrangement set forth below)

- Descriptive title of the invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the invention
- Brief Summary of the invention
- Brief Description of the drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the disclosure

3 ☐ Drawing(s) (35 U.S.C. 113) [Total]
Sheets

4 Oath or Declaration [Total 1]

- a. ☒ Newly unexecuted (original or copy)
- b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)

i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A
SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF
ONE FILED IN A PRIOR APPLICATION IS RELED UPON (37 C.F.R. § 1.28).

5 ☐ Microfiche Computer Program (Appendix)

6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☐ Computer Readable Copy
- b. ☒ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))

8. ☐ 37 C.F.R. § 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney

9. ☐ English Translation Document (if applicable)

10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations

11. ☐ Preliminary Amendment

12. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

13. ☒ *Small Entity Statement(s) ☐ Statement filed in prior application,
Status still proper and desired
(PTO/B/09-12)

14. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

15. ☐ Other:

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No:

Prior application information: Examiner

Group/Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

17. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label



or ☐ Correspondence address below

Name

24231

PATENT TRADEMARK OFFICE

Address

City

State

Zip Code

Country

Telephone

(281) 362-6554

Fax

(281) 364-0155

Name (Print/Type)

Lance K. Ishimoto

Registration No.

41866

Signature

Lance K. Ishimoto

Date

November 6, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(c)) -- SMALL BUSINESS CONCERN**

Docket Number (Optional)
LEX-0083-USA

Applicant, Patentee, or Identifier: Brian Mathur et al.

Application or Patent No.: _____

Filed or Issued: November 6, 2000

Title: Novel Human Kinase Protein and Polynucleotides Encoding the Same

I hereby state that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN Lexicon Genetics Incorporated

ADDRESS OF SMALL BUSINESS CONCERN 4000 Research Forest Drive, The Woodlands, TX 77381

I hereby state that the above identified small business concern qualifies as a small business concern as defined in 13 CFR Part 121 for purposes of paying reduced fees to the United States Patent and Trademark Office. Questions related to size standards for a small business concern may be directed to: Small Business Administration, Size Standards Staff, 409 Third Street, SW, Washington, DC 20416.

I hereby state that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☒ the specification filed herewith with title as listed above.
☐ the application identified above.
☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person concern, or organization having any rights in the invention is listed below:

- ☒ No such persons, concerns, or organizations exist.
☐ each such person, concerns, or organization is listed below:

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)


I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING Lance K. Ishimoto

TITLE OF PERSON IF OTHER THAN OWNER Vice President - Intellectual Property

ADDRESS OF PERSON SIGNING 4000 Research Forest Drive, The Woodlands, TX 77381

SIGNATURE



DATE November 6, 2000

Reg. No. 41,866

NOVEL HUMAN KINASE PROTEIN AND POLYNUCLEOTIDES ENCODING THE SAME

1. INTRODUCTION

5 The present application claims the benefit of U.S.
Provisional Application Number 60/164,289 which was filed on
November 8, 1999 and is herein incorporated by reference in
its entirety.

10 The present invention relates to the discovery,
identification, and characterization of novel human
polynucleotides encoding a protein that shares sequence
similarity with animal kinases. The invention encompasses
the described polynucleotides, host cell expression systems,
the encoded proteins, fusion proteins, polypeptides and
15 peptides, antibodies to the encoded proteins and peptides,
and genetically engineered animals that either lack or over
express the disclosed genes, antagonists and agonists of the
proteins, and other compounds that modulate the expression
or activity of the proteins encoded by the disclosed genes
20 that can be used for diagnosis, drug screening, clinical
trial monitoring and the treatment of physiological
disorders.

2. BACKGROUND OF THE INVENTION

25 Kinases mediate phosphorylation of a wide variety of
proteins and compounds in the cell. Along with
phosphatases, kinases are involved in a range of regulatory
pathways. Given the physiological importance of kinases,
they have been subject to intense scrutiny and are proven
drug targets.

30 3. SUMMARY OF THE INVENTION

The present invention relates to the discovery,
identification, and characterization of nucleotides that

encode a novel human protein, and the corresponding amino acid sequences of this protein. The novel human protein (NHP) described for the first time herein shares structural similarity with animal kinases, including, but not limited to serine/threonine protein kinases. As such, the novel polynucleotides encode a new kinase protein having homologues and orthologs across a range of phyla and species.

The novel human polynucleotides described herein, encode an open reading frame (ORF) encoding a protein of 893 amino acids in length (see SEQ ID NO: 2).

The invention also encompasses agonists and antagonists of the described NHP, including small molecules, large molecules, mutant NHPs, or portions thereof that compete with native NHP, peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHP (e.g., antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NHP polynucleotides (e.g., expression constructs that place the described gene under the control of a strong promoter system). The present invention also includes both transgenic animals that express a NHP transgene, and NHP "knock-outs" (which can be conditional) that do not express a functional NHP.

Further, the present invention also relates to processes for identifying compounds that modulate, *i.e.*, act as agonists or antagonists, of NHP expression and/or NHP product activity that utilize purified preparations of the described NHPs and/or NHP product, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.

4. DESCRIPTION OF THE SEQUENCE LISTING AND FIGURES

The Sequence Listing provides the sequence of a novel human ORF that encodes the described novel human kinase-like protein.

5. DETAILED DESCRIPTION OF THE INVENTION

The NHP, described for the first time herein, is a novel protein that is expressed in, *inter alia*, human cell lines, and human brain, pituitary, cerebellum, spinal cord, thymus, lymph node, bone marrow, trachea, kidney, liver, prostate, testis, thyroid, adrenal gland, pancreas, stomach, small intestine, colon, skeletal muscle, uterus, placenta, mammary gland, adipose, esophagus, bladder, cervix, rectum, pericardium, hypothalamus, ovary, fetal kidney, and fetal lung cells. The described sequences were compiled from gene trapped cDNAs, ESTs, a and human brain cDNA library, (Edge Biosystems, Gaithersburg, MD).

The present invention encompasses the nucleotides presented in the Sequence Listing, host cells expressing such nucleotides, the expression products of such nucleotides, and: (a) nucleotides that encode mammalian homologs of the described genes, including the specifically described NHP, and the NHP products; (b) nucleotides that encode one or more portions of the NHP that correspond to functional domains, and the polypeptide products specified by such nucleotide sequences, including but not limited to the novel regions of any active domain(s); (c) isolated nucleotides that encode mutant versions, engineered or naturally occurring, of the described NHP in which all or a part of at least one domain is deleted or altered, and the polypeptide products specified by such nucleotide sequences, including but not limited to soluble proteins and peptides

in which all or a portion of the signal sequence is deleted;
(d) nucleotides that encode chimeric fusion proteins

containing all or a portion of a coding region of a NHP, or
one of its domains (e.g., a receptor/ligand binding domain,

5 accessory protein/self-association domain, etc.) fused to
another peptide or polypeptide; or (e) therapeutic or
diagnostic derivatives of the described polynucleotides such
as oligonucleotides, antisense polynucleotides, ribozymes,
dsRNA, or gene therapy constructs comprising a sequence

10 first disclosed in the Sequence Listing. As discussed
above, the present invention includes: (a) the human DNA
sequences presented in the Sequence Listing (and vectors
comprising the same) and additionally contemplates any
nucleotide sequence encoding a contiguous NHP open reading
15 frame (ORF) that hybridizes to a complement of a DNA
sequence presented in the Sequence Listing under highly
stringent conditions, e.g., hybridization to filter-bound
DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM
EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C
20 (Ausubel F.M. et al., eds., 1989, Current Protocols in
Molecular Biology, Vol. I, Green Publishing Associates,
Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3)
and encodes a functionally equivalent gene product.

Additionally contemplated are any nucleotide sequences that
25 hybridize to the complement of the DNA sequence that encode
and express an amino acid sequence presented in the Sequence
Listing under moderately stringent conditions, e.g., washing
in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, *supra*),
yet still encode a functionally equivalent NHP product.

30 Functional equivalents of a NHP include naturally occurring
NHPs present in other species and mutant NHPs whether
naturally occurring or engineered (by site directed
mutagenesis, gene shuffling, directed evolution as described

in, for example, U.S. Patent No. 5,837,458). The invention also includes degenerate nucleic acid variants of the disclosed NHP polynucleotide sequences.

Additionally contemplated are polynucleotides encoding
5 NHP ORFs, or their functional equivalents, encoded by polynucleotide sequences that are about 99, 95, 90, or about 85 percent similar to corresponding regions of SEQ ID NO:1 (as measured by BLAST sequence comparison analysis using, for example, the GCG sequence analysis package using
10 default parameters).

The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore the complements of, the described NHP encoding polynucleotides. Such hybridization conditions can be
15 highly stringent or less highly stringent, as described above. In instances where the nucleic acid molecules are deoxyoligonucleotides ("DNA oligos"), such molecules are generally about 16 to about 100 bases long, or about 20 to about 80, or about 34 to about 45 bases long, or any
20 variation or combination of sizes represented therein that incorporate a contiguous region of sequence first disclosed in the Sequence Listing. Such oligonucleotides can be used in conjunction with the polymerase chain reaction (PCR) to screen libraries, isolate clones, and prepare cloning and
25 sequencing templates, etc.

Alternatively, such NHP oligonucleotides can be used as hybridization probes for screening libraries, and assessing gene expression patterns (particularly using a micro array or high-throughput "chip" format). Additionally, a series
30 of the described NHP oligonucleotide sequences, or the complements thereof, can be used to represent all or a portion of the described NHP sequences. The oligonucleotides, typically between about 16 to about 40 (or

any whole number within the stated range) nucleotides in length may partially overlap each other and/or the NHP sequence may be represented using oligonucleotides that do not overlap. Accordingly, the described NHP polynucleotide sequence shall typically comprise at least about two or three distinct oligonucleotide sequences of at least about 18, and preferably about 25, nucleotides in length that are each first disclosed in the described Sequence Listing. Such oligonucleotide sequences may begin at any nucleotide present within a sequence in the Sequence Listing and proceed in either a sense (5'-to-3') orientation vis-a-vis the described sequence or in an antisense orientation.

For oligonucleotide probes, highly stringent conditions may refer, e.g., to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos). These nucleic acid molecules may encode or act as NHP gene antisense molecules, useful, for example, in NHP gene regulation (for and/or as antisense primers in amplification reactions of NHP gene nucleic acid sequences). With respect to NHP gene regulation, such techniques can be used to regulate biological functions. Further, such sequences can be used as part of ribozyme and/or triple helix sequences that are also useful for NHP gene regulation.

Inhibitory antisense or double stranded oligonucleotides can additionally comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-

galactosylqueosine, inosine, N6-isopentenyladenine,
 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine,
 2-methyladenine, 2-methylguanine, 3-methylcytosine,
 5-methylcytosine, N6-adenine, 7-methylguanine,
 5 5-methylaminomethyluracil, 5-methoxyaminomethyl-
 2-thiouracil, beta-D-mannosylqueosine,
 5'-methoxycarboxymethyluracil, 5-methoxyuracil,
 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid
 (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine,
 10 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,
 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-
 5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-
 3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide can also comprise at
 15 least one modified sugar moiety selected from the group
 including but not limited to arabinose, 2-fluoroarabinose,
 xylulose, and hexose.

In yet another embodiment, the antisense
 oligonucleotide will comprise at least one modified
 20 phosphate backbone selected from the group consisting of a
 phosphorothioate, a phosphorodithioate, a
 phosphoramidothioate, a phosphoramidate, a
 phosphordiamidate, a methylphosphonate, an alkyl
 phosphotriester, and a formacetal or analog thereof.

25 In yet another embodiment, the antisense
 oligonucleotide is an α -anomeric oligonucleotide. An α -
 anomeric oligonucleotide forms specific double-stranded
 hybrids with complementary RNA in which, contrary to the
 usual β -units, the strands run parallel to each other
 30 (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The
 oligonucleotide is a 2'-O-methylribonucleotide (Inoue et
 al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-
 DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

Alternatively, double stranded RNA can be used to disrupt the expression and function of a targeted NHP.

Oligonucleotides of the invention can be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides can be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), and methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual (and periodic updates thereof), Cold Springs Harbor Press, N.Y.; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

Alternatively, suitably labeled NHP nucleotide probes can be used to screen a human genomic library using appropriately stringent conditions or by PCR. The identification and characterization of human genomic clones is helpful for identifying polymorphisms (including, but not limited to, nucleotide repeats, microsatellite alleles, single nucleotide polymorphisms, or coding single nucleotide polymorphisms), determining the genomic structure of a given locus/allele, and designing diagnostic tests. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within

the exons, introns, splice sites (e.g., splice acceptor and/or donor sites), etc., that can be used in diagnostics and pharmacogenomics.

Further, a NHP gene homolog can be isolated from nucleic acid from an organism of interest by performing PCR using two degenerate or "wobble" oligonucleotide primer pools designed on the basis of amino acid sequences within the NHP products disclosed herein. The template for the reaction may be total RNA, mRNA, and/or cDNA obtained by reverse transcription of mRNA prepared from, for example, human or non-human cell lines or tissue, such as prostate, rectum, colon, or adrenal gland, known or suspected to express an allele of a NHP gene.

The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequence of the desired NHP gene. The PCR fragment can then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment can be labeled and used to screen a cDNA library, such as a bacteriophage cDNA library.

Alternatively, the labeled fragment can be used to isolate genomic clones via the screening of a genomic library.

PCR technology can also be used to isolate full length cDNA sequences. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source (i.e., one known, or suspected, to express a NHP gene, such as, for example, testis tissue). A reverse transcription (RT) reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a complementary primer.

Thus, cDNA sequences upstream of the amplified fragment can be isolated. For a review of cloning strategies that can be used, see e.g., Sambrook *et al.*, 1989, *supra*.

A cDNA encoding a mutant NHP gene can be isolated, for example, by using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying a mutant NHP allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using these two primers, the product is then amplified via PCR, optionally cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant NHP allele to that of a corresponding normal NHP allele, the mutation(s) responsible for the loss or alteration of function of the mutant NHP gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry a mutant NHP allele (e.g., a person manifesting a NHP-associated phenotype such as, for example, immune disorders, obesity, high blood pressure, etc.), or a cDNA library can be constructed using RNA from a tissue known, or suspected, to express a mutant NHP allele. A normal NHP gene, or any suitable fragment thereof, can then be labeled and used as a probe to identify the corresponding mutant NHP allele in such libraries. Clones containing mutant NHP gene sequences can then be purified and subjected to sequence analysis according to methods well known to those skilled in the art.

Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant NHP allele in an individual suspected of or known to carry such a mutant allele. In this manner, gene products made by the putatively mutant tissue may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against a normal NHP product, as described below. (For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.)

Additionally, screening can be accomplished by screening with labeled NHP fusion proteins, such as, for example, alkaline phosphatase-NHP or NHP-alkaline phosphatase fusion proteins. In cases where a NHP mutation results in an expressed gene product with altered function (e.g., as a result of a missense or a frameshift mutation), polyclonal antibodies to a NHP are likely to cross-react with a corresponding mutant NHP gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known in the art.

An additional application of the described novel human polynucleotide sequences is their use in the molecular mutagenesis/evolution of proteins that are at least partially encoded by the described novel sequences using, for example, polynucleotide shuffling or related methodologies. Such approaches are described in U.S. Patents Nos. 5,830,721 and 5,837,458 which are herein incorporated by reference in their entirety.

The invention also encompasses (a) DNA vectors that contain any of the foregoing NHP coding sequences and/or their complements (i.e., antisense); (b) DNA expression

vectors that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences (for example, baculo virus as described in U.S. Patent No.

5 5,869,336 herein incorporated by reference); (c) genetically engineered host cells that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell; and (d) genetically engineered host cells
10 that express an endogenous NHP gene under the control of an exogenously introduced regulatory element (*i.e.*, gene activation). As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements known to
15 those skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the human cytomegalovirus (hCMV) immediate early gene, regulatable, viral elements (particularly retroviral LTR promoters), the early or late promoters of SV40 adenovirus,
20 the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase (PGK), the promoters of acid phosphatase, and the promoters of the yeast α -mating
25 factors.

Where, as in the present instance, some of the described NHP peptides or polypeptides are thought to be cytoplasmic proteins, expression systems can be engineered that produce soluble derivatives of a NHP (corresponding to
30 a NHP extracellular and/or intracellular domains, or truncated polypeptides lacking one or more hydrophobic domains) and/or NHP fusion protein products (especially NHP-Ig fusion proteins, *i.e.*, fusions of a NHP domain to an

IgFc), NHP antibodies, and anti-idiotypic antibodies (including Fab fragments) that can be used in therapeutic applications. Preferably, the above expression systems are engineered to allow the desired peptide or polypeptide to be recovered from the culture media.

Also encompassed by the present invention are novel protein constructs engineered in such a way that they facilitate transport of the NHP to the target site, to the desired organ, across the cell membrane and/or to the nucleus where the NHP can exert its function activity. This goal can be achieved by coupling of the NHP to a cytokine or other ligand that would direct the NHP to the target organ and facilitate receptor mediated transport across the membrane into the cytosol. Conjugation of NHPs to antibody molecules or their Fab fragments could be used to target cells bearing a particular epitope. Attaching the appropriate signal sequence to the NHP would also transport the NHP to the desired location within the cell. Alternatively targeting of NHP or its nucleic acid sequence can be achieved using liposome or lipid complex based delivery systems. Such technologies are described in U.S. Patents Nos. 4,594,595, 5,459,127, 5,948,767 and 6,110,490 and their respective disclosures which are herein incorporated by reference in their entirety.

The present invention also encompasses antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists and agonists of the NHP, as well as compounds or nucleotide constructs that inhibit expression of a NHP gene (transcription factor inhibitors, antisense and ribozyme molecules, or gene or regulatory sequence replacement constructs), or promote the expression of a NHP (e.g., expression constructs in which NHP coding sequences are

operatively associated with expression control elements such as promoters, promoter/enhancers, etc.).

The NHPs or NHP peptides, NHP fusion proteins, NHP nucleotide sequences, antibodies, antagonists and agonists
5 can be useful for the detection of mutant NHPs or inappropriately expressed NHPs for the diagnosis of disease. The NHP proteins or peptides, NHP fusion proteins, NHP nucleotide sequences, host cell expression systems, antibodies, antagonists, agonists and genetically engineered
10 cells and animals can be used for screening for drugs (or high throughput screening of combinatorial libraries) effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body. The use of engineered host cells and/or animals
15 can offer an advantage in that such systems allow not only for the identification of compounds that bind to the endogenous receptor/ligand of a NHP, but can also identify compounds that trigger NHP-mediated activities or pathways.

Finally, the NHP products can be used as therapeutics.
20 For example, soluble derivatives such as NHP peptides/domains corresponding the NHPs, NHP fusion protein products (especially NHP-Ig fusion proteins, *i.e.*, fusions of a NHP, or a domain of a NHP, to an IgFc), NHP antibodies and anti-idiotypic antibodies (including Fab fragments),
25 antagonists or agonists (including compounds that modulate or act on downstream targets in a NHP-mediated pathway) can be used to directly treat diseases or disorders. For instance, the administration of an effective amount of soluble NHP, or a NHP-IgFc fusion protein or an anti-
30 idiotypic antibody (or its Fab) that mimics the NHP could activate or effectively antagonize the endogenous NHP or a protein interactive therewith. Nucleotide constructs encoding such NHP products can be used to genetically

engineer host cells to express such products *in vivo*; these genetically engineered cells function as "bioreactors" in the body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide constructs encoding functional NHPs, mutant NHPs, as well as antisense and ribozyme molecules can also be used in "gene therapy" approaches for the modulation of NHP expression. Thus, the invention also encompasses pharmaceutical formulations and methods for treating biological disorders.

Various aspects of the invention are described in greater detail in the subsections below.

5.1 THE NHP SEQUENCES

The cDNA sequence and the corresponding deduced amino acid sequence of the described NHP are presented in the Sequence Listing. The NHP nucleotide sequences were obtained from a human cDNA library using probes and/or primers generated from human gene trapped sequence tags.

Expression analysis has provided evidence that the described NHPs can be expressed in human tissues as well as gene trapped human cells. In addition to the serine/threonine kinases, the described NHPs also share significant similarity to a range of additional kinase families such as cell division protein kinases, cyclin dependent kinase, etc. from a range of phyla and species. Given the physiological importance of protein kinases, they have been subject to intense scrutiny as exemplified and discussed in U.S. Patent No. 5,817,479 herein incorporated by reference in its entirety.

5.2 NHPS AND NHP POLYPEPTIDES

NHPs, polypeptides, peptide fragments, mutated, truncated, or deleted forms of the NHPs, and/or NHP fusion

proteins can be prepared for a variety of uses. These uses include, but are not limited to, the generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products related to a NHP, as reagents in assays for screening for compounds that can be as pharmaceutical reagents useful in the therapeutic treatment of mental, biological, or medical disorders and disease.

The Sequence Listing discloses the amino acid sequence encoded by the described NHP-encoding polynucleotides. The NHP has an initiator methionine in a DNA sequence context consistent with eucaryotic translation initiation site.

The NHP amino acid sequence of the invention include the amino acid sequence presented in the Sequence Listing as well as analogues and derivatives thereof. Further, corresponding NHP homologues from other species are encompassed by the invention. In fact, any NHP protein encoded by the NHP nucleotide sequences described above are within the scope of the invention, as are any novel polynucleotide sequences encoding all or any novel portion of an amino acid sequence presented in the Sequence Listing. The degenerate nature of the genetic code is well known, and, accordingly, each amino acid presented in the Sequence Listing, is generically representative of the well known nucleic acid "triplet" codon, or in many cases codons, that can encode the amino acid. As such, as contemplated herein, the amino acid sequences presented in the Sequence Listing, when taken together with the genetic code (see, for example, Table 4-1 at page 109 of "Molecular Cell Biology", 1986, J. Darnell et al. eds., Scientific American Books, New York, NY, herein incorporated by reference) are generically representative of all the various permutations and

combinations of nucleic acid sequences that can encode such amino acid sequences.

The invention also encompasses proteins that are functionally equivalent to the NHPs encoded by the presently described nucleotide sequences as judged by any of a number of criteria, including, but not limited to, the ability to bind and modify a NHP substrate, or the ability to effect an identical or complementary downstream pathway, or a change in cellular metabolism (e.g., proteolytic activity, ion flux, tyrosine phosphorylation, etc.). Such functionally equivalent NHP proteins include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the NHP nucleotide sequences described above, but which result in a silent change, thus producing a functionally equivalent gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

A variety of host-expression vector systems can be used to express the NHP nucleotide sequences of the invention. Where the NHP peptide or polypeptide can exist, or has been engineered to exist, as a soluble or secreted molecule, the soluble NHP peptide or polypeptide can be recovered from the culture media. Such expression systems also encompass engineered host cells that express a NHP, or functional

equivalent, *in situ*. Purification or enrichment of a NHP from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of the NHP, but to assess biological activity, e.g., in drug screening assays.

The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing NHP nucleotide sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing NHP nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing NHP sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing NHP nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the NHP product being expressed. For example, when a large quantity of such a protein is to be produced

for the generation of pharmaceutical compositions of or containing NHP, or for raising antibodies to a NHP, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such
5 vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which a NHP coding sequence may be ligated individually into the vector in frame with the *lacZ* coding region so that a fusion protein is produced; pIN vectors
10 (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are
15 soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released
20 from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhydrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. A NHP encoding polynucleotide sequence can be cloned
25 individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of NHP gene coding sequence will result in inactivation of the polyhedrin gene and production of
30 non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed

(e.g., see Smith et al., 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the NHP nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene can then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a NHP product in infected hosts (e.g., See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted NHP nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire NHP gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of a NHP coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators,

etc. (See Bittner et al., 1987, Methods in Enzymol. 153:516-544).

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, human cell lines.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the NHP sequences described above can be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded

into cell lines. This method may advantageously be used to engineer cell lines which express the NHP product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the NHP product.

A number of selection systems can be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, *et al.*, 1977, *Cell* 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, *Proc. Natl. Acad. Sci. USA* 48:2026), and adenine phosphoribosyltransferase (Lowy, *et al.*, 1980, *Cell* 22:817) genes can be employed in tk⁻, hgp⁻ or ap⁻ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler, *et al.*, 1980, *Natl. Acad. Sci. USA* 77:3567; O'Hare, *et al.*, 1981, *Proc. Natl. Acad. Sci. USA* 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, *et al.*, 1981, *J. Mol. Biol.* 150:1); and hyg^r, which confers resistance to hygromycin (Santerre, *et al.*, 1984, *Gene* 30:147).

Alternatively, any fusion protein can be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht *et al.* allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, *et al.*, 1991, *Proc. Natl. Acad. Sci. USA* 88:8972-8976). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an

amino-terminal tag consisting of six histidine residues.
Extracts from cells infected with recombinant vaccinia virus
are loaded onto Ni²⁺ nitriloacetic acid-agarose columns and
histidine-tagged proteins are selectively eluted with
5 imidazole-containing buffers.

5.3 ANTIBODIES TO NHP PRODUCTS

Antibodies that specifically recognize one or more
epitopes of a NHP, or epitopes of conserved variants of a
10 NHP, or peptide fragments of a NHP are also encompassed by
the invention. Such antibodies include but are not limited
to polyclonal antibodies, monoclonal antibodies (mAbs),
humanized or chimeric antibodies, single chain antibodies,
Fab fragments, F(ab')₂ fragments, fragments produced by a
15 Fab expression library, anti-idiotypic (anti-Id) antibodies,
and epitope-binding fragments of any of the above.

The antibodies of the invention can be used, for
example, in the detection of NHP in a biological sample and
may, therefore, be utilized as part of a diagnostic or
prognostic technique whereby patients may be tested for
20 abnormal amounts of NHP. Such antibodies may also be
utilized in conjunction with, for example, compound
screening schemes for the evaluation of the effect of test
compounds on expression and/or activity of a NHP gene
25 product. Additionally, such antibodies can be used in
conjunction gene therapy to, for example, evaluate the
normal and/or engineered NHP-expressing cells prior to their
introduction into the patient. Such antibodies may
additionally be used as a method for the inhibition of
30 abnormal NHP activity. Thus, such antibodies may,
therefore, be utilized as part of treatment methods.

For the production of antibodies, various host animals
may be immunized by injection with the NHP, an NHP peptide

(e.g., one corresponding to a functional domain of an NHP), truncated NHP polypeptides (NHP in which one or more domains have been deleted), functional equivalents of the NHP or mutated variant of the NHP. Such host animals may include but are not limited to pigs, rabbits, mice, goats, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's adjuvant (complete and incomplete), mineral salts such as aluminum hydroxide or aluminum phosphate, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Alternatively, the immune response could be enhanced by combination and or coupling with molecules such as keyhole limpet hemocyanin, tetanus toxoid, diphtheria toxoid, ovalbumin, cholera toxin or fragments thereof. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, *Nature* 256:495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, *Immunology Today* 4:72; Cole et al., 1983, *Proc. Natl. Acad. Sci. USA* 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, *Monoclonal Antibodies And Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.

The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.

5 In addition, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, *Proc. Natl. Acad. Sci.*, 81:6851-6855; Neuberger *et al.*, 1984, *Nature*, 312:604-608; Takeda *et al.*, 1985, *Nature*, 314:452-454) by splicing the genes from a mouse antibody molecule of
10 appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from
15 a murine mAb and a human immunoglobulin constant region. Such technologies are described in U.S. Patents Nos. 6,075,181 and 5,877,397 and their respective disclosures which are herein incorporated by reference in their entirety.

20 Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, *Science* 242:423-426; Huston *et al.*, 1988, *Proc. Natl. Acad. Sci. USA* 85:5879-5883; and Ward *et al.*, 1989, *Nature* 334:544-546) can be adapted to produce single chain
25 antibodies against NHP gene products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

30 Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: the $F(ab')_2$ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be

generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to a NHP can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" a given NHP, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example antibodies which bind to a NHP domain and competitively inhibit the binding of NHP to its cognate receptor/ligand can be used to generate anti-idiotypes that "mimic" the NHP and, therefore, bind, activate, or neutralize a NHP, NHP receptor, or NHP ligand. Such anti-idiotypic antibodies or Fab fragments of such anti-idiotypes can be used in therapeutic regimens involving a NHP mediated pathway.

The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. All cited publications, patents, and patent applications are herein incorporated by reference in their entirety.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising
at least 24 contiguous bases of nucleotide sequence first
5 disclosed in the NHP gene described in SEQ ID NO: 1.

2. An isolated nucleic acid molecule comprising
a nucleotide sequence that:

- (a) encodes the amino acid sequence shown in SEQ
10 ID NO: 2; and
- (b) hybridizes under stringent conditions to the
nucleotide sequence of SEQ ID NO: 1 or the
complement thereof.

5. An isolated nucleic acid molecule comprising
a nucleotide sequence encoding the amino acid sequence shown
in SEQ ID NO:2.

ABSTRACT

Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

PATENT APPLICATION

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

ATTORNEY DOCKET NO. LEX-0083-USA

As a below named inventor, I hereby declare that:

My residence/post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Novel Human Kinase Protein and Polynucleotides Encoding the Same

the specification of which is attached hereto unless the following box is checked:

☐ was filed on _____ as US Application Serial No. or PCT International Application
Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

Foreign Application(s) and/or Claim of Foreign Priority

I hereby claim foreign priority benefits under Title 35, United States Code Section 119 of any foreign application(s) for patent or inventor(s) certificate listed below and have also identified below any foreign application for patent or inventor(s) certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NUMBER	DATE FILED	PRIORITY CLAIMED UNDER 35 U.S.C. 119
			YES: _____ NO: _____
			YES: _____ NO: _____

Provisional Application

I hereby claim the benefit under Title 35, United States Code Section 119(e) of any United States provisional application(s) listed below:

APPLICATION SERIAL NUMBER	FILING DATE
60/164,289	11/8/1999

U.S. Priority Claim

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NUMBER	FILING DATE	STATUS(patented/pending/abandoned)

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) listed below to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Lance K. Ishimoto, Reg. No. 41866

Send Correspondence to:

Lance K. Ishimoto
Lexicon Genetics Incorporated
4000 Research Forest Drive
The Woodlands, TX 77381

Direct Telephone Calls To:

Lance K. Ishimoto
(281) 362-6554

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or patent issued thereon.

**DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION (continued)**

ATTORNEY DOCKET NO. LEX-0083-USA

Full Name of Inventor: Brian Mathur Citizenship: USA

Residence: 12000 Sawmill Road #2014, The Woodlands, TX 77380

Post Office Address: Same

Inventor's Signature _____ Date _____

Full Name of Inventor: C. Alexander Turner, Jr. Citizenship: USA

Residence: 67 Winter Wheat Place, The Woodlands, TX 77381

Post Office Address: Same

Inventor's Signature _____ Date _____

Full Name of Inventor: Alejandro Abuin Citizenship: Spain

Residence: 19 Belcarra Place, The Woodlands, TX 77382

Post Office Address: Same

Inventor's Signature _____ Date _____

Full Name of Inventor: Glenn Friedrich Citizenship: Canada

Residence: c/o Breland & Breland, Houston, TX 77004

Post Office Address: Same

Inventor's Signature _____ Date _____

Full Name of Inventor: Brian Zambrowicz Citizenship: USA

Residence: 18 Firethorne Place, The Woodlands, TX 77382

Post Office Address: Same

Inventor's Signature _____ Date _____

Full Name of Inventor: Arthur T. Sands Citizenship: USA

Residence: 163 Bristol Bend Circle, The Woodlands, TX 77382

Post Office Address: Same

Inventor's Signature _____ Date _____

SEQUENCE LISTING

<110> Mathur, Brian
Turner, C. Alexander Jr.
Abuin, Alejandro
Friedrich, Glenn
Zambrowicz, Brian
Sands, Arthur T.

<120> Novel Human Kinase Protein and
Polynucleotides Encoding the Same

<130> LEX-0083-USA

<150> US 60/164,289

<151> 1999-11-08

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2682

<212> DNA

<213> homo sapiens

<400> 1

atgtttcccc	tgaaggacgc	tgaaatggga	gcctttacct	tctttgcctc	ggctctgcca	60
catgatgttt	gtggaagcaa	tggacttcct	ctcacaccaa	attccatcaa	aatttttaggg	120
cgctttcaaa	tccttaaaac	catcacccat	cccagactct	gccagtatgt	ggatatttct	180
aggggaaagc	atgaacgact	agtggctcgtg	gctgaacatt	gtgaacgtag	tctggaagac	240
ttgcttcgag	aaaggaaacc	tgtgagctgt	tcaacggttt	tgtgtatagc	atttgagggt	300
cttcagggct	tgcagtatat	gaacaaacat	ggtatagtac	acagggcatt	gtctcctcat	360
aatatcctgt	tggaccgaaa	gggacatatt	aaattggcta	aattttggact	ttatcacatg	420
acagctcatg	gtgatgatgt	tgattttccca	atagggtatc	cctcgtactt	ggcccttgag	480
gtaattgcac	agggaatttt	caaaaccact	gatcacatgc	caagtaaaaa	accattgcct	540
tctggcccca	aatcagatgt	atgggtctctt	ggaatcattt	tattttgagct	ttgtgtggga	600
agaaaattat	ttcagagctt	ggatatttctt	gaaagactaa	aattttttgct	tactttggat	660
tgtgtagatg	acactttaat	agttctggct	gaagagcatg	gttgtttgga	cattataaag	720
gagcttcctg	aaactgtgat	agatcttttg	aataagtgcc	ttaccttcca	tccttctaag	780
aggccaaccc	cagatgaatt	aatgaaggac	aaagtattca	gtgaggtatc	acctttatat	840
accccttta	ccaaacctgc	cagtctgttt	tcatcttctc	tgagatgtgc	tgatttaact	900
ctgcctgagg	atatcagtca	gttgtgtaaa	gatataaata	atgattacct	ggcagaaaga	960
tctattgaag	aagtgtatta	cctttgggtg	ttggctggag	gtgacttgga	gaaagagctt	1020
gtcaacaagg	aaatcattcg	atccaaacca	cctatctgca	cactccccaa	ttttctcttt	1080
gaggatgggtg	aaagcttttg	acaaggtcga	gatagaagct	cgctttttaga	tgataccact	1140
gtgacattgt	cgttatgcca	gctaagaaat	agattgaaag	atggttggtg	agaagcattt	1200
taccattac	ttgaagatga	ccagtcta	ttacctcatt	caaacagcaa	taatgagttg	1260
tctgcagctg	ccacgctccc	tttaatcatc	agagagaagg	atacagagta	ccaactaaat	1320
agaattattc	tcttcgacag	gctgctaaag	gcttatccat	ataaaaaaaa	ccaaatctgg	1380
aaagaagcaa	gagttgacat	tcctcctctt	atgagagggt	taacctgggc	tgctcttctg	1440
ggagttgagg	gagctattca	tgccaagtac	gatgcaattg	ataaagacac	tccaattcct	1500
acagatagac	aaattgaagt	ggatattcct	cgctgtcatc	agtacgatga	actgttatca	1560
tcaccagaag	gtcatgcaaa	atttaggcgt	gtattaaaag	cctgggtagt	gtctcatcct	1620

gatcttgtgt attggcaagg tcttgactca ctttgtgctc cattcctata tctaaacttc 1680
aataatgaag ccttggctta tgcattgtatg tctgctttta ttcccaaata cctgtataac 1740
ttcttcttaa aagacaactc acatgtaata caagagtatc tgactgtctt ctctcagatg 1800
attgcatttc atgatccaga gctgagtaat catctcaatg agattgggtt cattccagat 1860
ctctatgccca tcccttggtt tcttaccatg tttactcatg tatttccact acacaaaatt 1920
ttccacctct gggatacctt actacttggg aattcctctt tcccattctg tattggagta 1980
gcaattcttc agcagctgcg ggaccggctt ttggctaata gctttaatga gtgtattctt 2040
ctcttctccg atttaccaga aattgacatt gaacgctgtg tgagagaatc tatcaacctg 2100
ttttgttggc ctcctaaaag tgctacttac agacagcatg ctcaacctcc aaagccatct 2160
tctgacagca gtggaggcag aagttcggca ccttatttct ctgctgagtg tccagatcct 2220
ccaagacag atctgtcaag agaattccatc ccattaaatg acctgaagtc agaagtatca 2280
ccaaggattt cagcagagga cctgattgac ttgtgtgagc tcacagtgc aggccacttc 2340
aaaacacca gcaagaaaac aaagtccagt aaaccaaagc tcttgggtgtg tgacatccgg 2400
aatagtggaag actttattcg tggtcacatt tcaggaagca tcaacattcc attcagtgc 2460
gccttcactg cagaagggga gcttaccag ggcccttaca ctgctatgct ccagaacttc 2520
aaaggggaagg tcattgtcat cgtggggcat gtggcaaac acacagctga gtttgcagct 2580
caccttgtga agatgaaata tccaagaatc tgtattctag atggtggcat taataaaata 2640
aagccaacag gcctcctcac catcccatct cctcaaatat ga 2682

<210> 2

<211> 893

<212> PRT

<213> homo sapiens

<400> 2

Met Phe Pro Leu Lys Asp Ala Glu Met Gly Ala Phe Thr Phe Phe Ala
1 5 10 15
Ser Ala Leu Pro His Asp Val Cys Gly Ser Asn Gly Leu Pro Leu Thr
20 25 30
Pro Asn Ser Ile Lys Ile Leu Gly Arg Phe Gln Ile Leu Lys Thr Ile
35 40 45
Thr His Pro Arg Leu Cys Gln Tyr Val Asp Ile Ser Arg Gly Lys His
50 55 60
Glu Arg Leu Val Val Val Ala Glu His Cys Glu Arg Ser Leu Glu Asp
65 70 75 80
Leu Leu Arg Glu Arg Lys Pro Val Ser Cys Ser Thr Val Leu Cys Ile
85 90 95
Ala Phe Glu Val Leu Gln Gly Leu Gln Tyr Met Asn Lys His Gly Ile
100 105 110
Val His Arg Ala Leu Ser Pro His Asn Ile Leu Leu Asp Arg Lys Gly
115 120 125
His Ile Lys Leu Ala Lys Phe Gly Leu Tyr His Met Thr Ala His Gly
130 135 140
Asp Asp Val Asp Phe Pro Ile Gly Tyr Pro Ser Tyr Leu Ala Pro Glu
145 150 155 160
Val Ile Ala Gln Gly Ile Phe Lys Thr Thr Asp His Met Pro Ser Lys
165 170 175
Lys Pro Leu Pro Ser Gly Pro Lys Ser Asp Val Trp Ser Leu Gly Ile
180 185 190
Ile Leu Phe Glu Leu Cys Val Gly Arg Lys Leu Phe Gln Ser Leu Asp
195 200 205
Ile Ser Glu Arg Leu Lys Phe Leu Leu Thr Leu Asp Cys Val Asp Asp
210 215 220
Thr Leu Ile Val Leu Ala Glu Glu His Gly Cys Leu Asp Ile Ile Lys
225 230 235 240
Glu Leu Pro Glu Thr Val Ile Asp Leu Leu Asn Lys Cys Leu Thr Phe

009377-1060

				245					250					255			
His	Pro	Ser	Lys	Arg	Pro	Thr	Pro	Asp	Glu	Leu	Met	Lys	Asp	Lys	Val		
			260					265					270				
Phe	Ser	Glu	Val	Ser	Pro	Leu	Tyr	Thr	Pro	Phe	Thr	Lys	Pro	Ala	Ser		
		275					280					285					
Leu	Phe	Ser	Ser	Ser	Leu	Arg	Cys	Ala	Asp	Leu	Thr	Leu	Pro	Glu	Asp		
		290				295					300						
Ile	Ser	Gln	Leu	Cys	Lys	Asp	Ile	Asn	Asn	Asp	Tyr	Leu	Ala	Glu	Arg		
305					310					315					320		
Ser	Ile	Glu	Glu	Val	Tyr	Tyr	Leu	Trp	Cys	Leu	Ala	Gly	Gly	Asp	Leu		
			325					330						335			
Glu	Lys	Glu	Leu	Val	Asn	Lys	Glu	Ile	Ile	Arg	Ser	Lys	Pro	Pro	Ile		
			340					345					350				
Cys	Thr	Leu	Pro	Asn	Phe	Leu	Phe	Glu	Asp	Gly	Glu	Ser	Phe	Gly	Gln		
		355					360					365					
Gly	Arg	Asp	Arg	Ser	Ser	Leu	Leu	Asp	Asp	Thr	Thr	Val	Thr	Leu	Ser		
	370					375					380						
Leu	Cys	Gln	Leu	Arg	Asn	Arg	Leu	Lys	Asp	Val	Gly	Gly	Glu	Ala	Phe		
385					390					395					400		
Tyr	Pro	Leu	Leu	Glu	Asp	Asp	Gln	Ser	Asn	Leu	Pro	His	Ser	Asn	Ser		
			405					410						415			
Asn	Asn	Glu	Leu	Ser	Ala	Ala	Ala	Thr	Leu	Pro	Leu	Ile	Ile	Arg	Glu		
		420						425					430				
Lys	Asp	Thr	Glu	Tyr	Gln	Leu	Asn	Arg	Ile	Ile	Leu	Phe	Asp	Arg	Leu		
	435						440					445					
Leu	Lys	Ala	Tyr	Pro	Tyr	Lys	Lys	Asn	Gln	Ile	Trp	Lys	Glu	Ala	Arg		
	450					455					460						
Val	Asp	Ile	Pro	Pro	Leu	Met	Arg	Gly	Leu	Thr	Trp	Ala	Ala	Leu	Leu		
465					470					475					480		
Gly	Val	Glu	Gly	Ala	Ile	His	Ala	Lys	Tyr	Asp	Ala	Ile	Asp	Lys	Asp		
			485					490						495			
Thr	Pro	Ile	Pro	Thr	Asp	Arg	Gln	Ile	Glu	Val	Asp	Ile	Pro	Arg	Cys		
		500						505					510				
His	Gln	Tyr	Asp	Glu	Leu	Leu	Ser	Ser	Pro	Glu	Gly	His	Ala	Lys	Phe		
	515						520				525						
Arg	Arg	Val	Leu	Lys	Ala	Trp	Val	Val	Ser	His	Pro	Asp	Leu	Val	Tyr		
	530					535					540						
Trp	Gln	Gly	Leu	Asp	Ser	Leu	Cys	Ala	Pro	Phe	Leu	Tyr	Leu	Asn	Phe		
545					550					555					560		
Asn	Asn	Glu	Ala	Leu	Ala	Tyr	Ala	Cys	Met	Ser	Ala	Phe	Ile	Pro	Lys		
		565						570					575				
Tyr	Leu	Tyr	Asn	Phe	Phe	Leu	Lys	Asp	Asn	Ser	His	Val	Ile	Gln	Glu		
	580							585					590				
Tyr	Leu	Thr	Val	Phe	Ser	Gln	Met	Ile	Ala	Phe	His	Asp	Pro	Glu	Leu		
	595						600					605					
Ser	Asn	His	Leu	Asn	Glu	Ile	Gly	Phe	Ile	Pro	Asp	Leu	Tyr	Ala	Ile		
	610					615					620						
Pro	Trp	Phe	Leu	Thr	Met	Phe	Thr	His	Val	Phe	Pro	Leu	His	Lys	Ile		
625					630					635					640		
Phe	His	Leu	Trp	Asp	Thr	Leu	Leu	Leu	Gly	Asn	Ser	Ser	Phe	Pro	Phe		
			645						650					655			
Cys	Ile	Gly	Val	Ala	Ile	Leu	Gln	Gln	Leu	Arg	Asp	Arg	Leu	Leu	Ala		
		660					665						670				
Asn	Gly	Phe	Asn	Glu	Cys	Ile	Leu	Leu	Phe	Ser	Asp	Leu	Pro	Glu	Ile		
	675					680					685						
Asp	Ile	Glu	Arg	Cys	Val	Arg	Glu	Ser	Ile	Asn	Leu	Phe	Cys	Trp	Thr		

